Mitochondrial oxidative phosphorylation disorder
MONDO:0016387A multisystem disorder with variable manifestations resulting from a defect in the mitochondrial oxidative phosphorylation (OXPHOS) system.
Also known as: OXPHOS disease, OXPHOS system deficiency
63 clinical trials for this condition and its sub-types, 3 tagged with Mitochondrial oxidative phosphorylation disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Mitochondrial oxidative phosphorylation disorder
-
Leber hereditary optic neuropathy 18 trials
1 sub-type
- Leber optic atrophy and dystonia 0 trials
-
Mitochondrial DNA depletion syndrome 3 trials · 11 incl. sub-types
21 sub-types
- Mitochondrial DNA depletion syndrome, hepatocerebral form 0 trials · 4 incl. sub-types Sub-types →
- Mitochondrial DNA depletion syndrome, myopathic form 4 trials
- AFG3L2-related optic atrophy and/or spastic ataxia spectrum 0 trials Sub-types →
- Sengers syndrome 0 trials
- Mitochondrial DNA deletion syndrome with progressive myopathy 0 trials
- Mitochondrial DNA depletion syndrome 1 0 trials
- Mitochondrial DNA depletion syndrome 11 0 trials
- Mitochondrial DNA depletion syndrome 12A (cardiomyopathic type), autosomal dominant 0 trials
- Mitochondrial DNA depletion syndrome 12B (cardiomyopathic type), autosomal recessive 0 trials
- Mitochondrial DNA depletion syndrome 14B (cardioencephalomyopathic type) 0 trials
- Mitochondrial DNA depletion syndrome 15 (hepatocerebral type) 0 trials
- Mitochondrial DNA depletion syndrome 16 (hepatic type) 0 trials
- Mitochondrial DNA depletion syndrome 17 0 trials
- Mitochondrial DNA depletion syndrome 18 0 trials
- Mitochondrial DNA depletion syndrome 19 0 trials
- Mitochondrial DNA depletion syndrome 20 (mngie type) 0 trials
- Mitochondrial DNA depletion syndrome 4b 0 trials
- Mitochondrial DNA depletion syndrome, encephalomyopathic form 0 trials Sub-types →
- Mitochondrial dna depletion syndrome 14A (encephalomyopathic type) 0 trials
- Mitochondrial dna depletion syndrome 16B (neuroophthalmic type) 0 trials
- Mitochondrial dna depletion syndrome 21 0 trials
-
Leigh syndrome 9 trials
4 sub-types
-
Kearns-Sayre syndrome 5 trials
-
Mitochondrial respiratory chain complex deficiency 4 trials · 5 incl. sub-types
9 sub-types
- Mitochondrial complex I deficiency 2 trials Sub-types →
- Mitochondrial complex IV deficiency, nuclear-type 1 trial Sub-types →
- SDHC-related Mitochondrial Disease 0 trials
- Mitochondrial complex III deficiency 0 trials Sub-types →
- Mitochondrial complex V (ATP synthase) deficiency, nuclear type 1 0 trials
- Mitochondrial complex V (ATP synthase) deficiency, nuclear type 2 0 trials
- Mitochondrial complex V (ATP synthase) deficiency, nuclear type 3 0 trials
- Mitochondrial complex V (ATP synthase) deficiency, nuclear type 4B 0 trials
- Mitochondrial complex V (ATP synthase) deficiency, nuclear type 5 0 trials
-
Deafness, aminoglycoside-induced 4 trials
-
NARP syndrome 3 trials
-
Coenzyme Q10 deficiency 3 trials
10 sub-types
- COQ7-related distal hereditary motor neuropathy 0 trials
- Autosomal recessive ataxia due to ubiquinone deficiency 0 trials
- Coenzyme Q10 deficiency, primary, 1 0 trials
- Coenzyme Q10 deficiency, primary, 3 0 trials
- Coenzyme q10 deficiency, primary, 9 0 trials
- Deafness-encephaloneuropathy-obesity-valvulopathy syndrome 0 trials
- Encephalopathy-hypertrophic cardiomyopathy-renal tubular disease syndrome 0 trials
- Familial steroid-resistant nephrotic syndrome with sensorineural deafness 0 trials
- Neonatal encephalomyopathy-cardiomyopathy-respiratory distress syndrome 0 trials
- Primary coenzyme Q10 deficiency 8 0 trials
-
3 sub-types
-
Ataxia neuropathy spectrum 2 trials
2 sub-types
-
Pontocerebellar hypoplasia type 6 2 trials
-
Leber plus disease 1 trial · 2 incl. sub-types
2 sub-types
-
Hereditary spastic paraplegia 7 1 trial
-
Charcot-Marie-Tooth disease type 4K 0 trials
-
Perrault syndrome 0 trials
7 sub-types
- Perrault syndrome 1 0 trials
- Perrault syndrome 2 0 trials
- Perrault syndrome 3 0 trials
- Perrault syndrome 4 0 trials
- Perrault syndrome 5 0 trials
- Perrault syndrome 6 0 trials
- Perrault syndrome 7 0 trials
-
58 sub-types
- Combined oxidative phosphorylation defect type 11 0 trials
- Combined oxidative phosphorylation defect type 13 0 trials
- Combined oxidative phosphorylation defect type 14 0 trials
- Combined oxidative phosphorylation defect type 15 0 trials
- Combined oxidative phosphorylation defect type 17 0 trials
- Combined oxidative phosphorylation defect type 2 0 trials
- Combined oxidative phosphorylation defect type 20 0 trials
- Combined oxidative phosphorylation defect type 21 0 trials
- Combined oxidative phosphorylation defect type 23 0 trials
- Combined oxidative phosphorylation defect type 24 0 trials
- Combined oxidative phosphorylation defect type 25 0 trials
- Combined oxidative phosphorylation defect type 26 0 trials
- Combined oxidative phosphorylation defect type 27 0 trials
- Combined oxidative phosphorylation defect type 30 0 trials
- Combined oxidative phosphorylation defect type 4 0 trials
- Combined oxidative phosphorylation defect type 7 0 trials
- Combined oxidative phosphorylation defect type 8 0 trials
- Combined oxidative phosphorylation defect type 9 0 trials
- Combined oxidative phosphorylation deficiency 19 0 trials
- Combined oxidative phosphorylation deficiency 28 0 trials
- Combined oxidative phosphorylation deficiency 29 0 trials
- Combined oxidative phosphorylation deficiency 32 0 trials
- Combined oxidative phosphorylation deficiency 33 0 trials
- Combined oxidative phosphorylation deficiency 34 0 trials
- Combined oxidative phosphorylation deficiency 35 0 trials
- Combined oxidative phosphorylation deficiency 36 0 trials
- Combined oxidative phosphorylation deficiency 37 0 trials
- Combined oxidative phosphorylation deficiency 38 0 trials
- Combined oxidative phosphorylation deficiency 39 0 trials
- Combined oxidative phosphorylation deficiency 40 0 trials
- Combined oxidative phosphorylation deficiency 41 0 trials
- Combined oxidative phosphorylation deficiency 42 0 trials
- Combined oxidative phosphorylation deficiency 43 0 trials
- Combined oxidative phosphorylation deficiency 44 0 trials
- Combined oxidative phosphorylation deficiency 45 0 trials
- Combined oxidative phosphorylation deficiency 46 0 trials
- Combined oxidative phosphorylation deficiency 47 0 trials
- Combined oxidative phosphorylation deficiency 48 0 trials
- Combined oxidative phosphorylation deficiency 51 0 trials
- Combined oxidative phosphorylation deficiency 52 0 trials
- Combined oxidative phosphorylation deficiency 53 0 trials
- Combined oxidative phosphorylation deficiency 54 0 trials
- Combined oxidative phosphorylation deficiency 55 0 trials
- Combined oxidative phosphorylation deficiency 56 0 trials
- Combined oxidative phosphorylation deficiency 57 0 trials
- Combined oxidative phosphorylation deficiency 58 0 trials
- Combined oxidative phosphorylation deficiency 59 0 trials
- Combined oxidative phosphorylation deficiency 60 0 trials
- Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3 0 trials
- Growth and developmental delay-hypotonia-vision impairment-lactic acidosis syndrome 0 trials
- Hepatoencephalopathy due to combined oxidative phosphorylation defect type 1 0 trials
- Hypotonia with lactic acidemia and hyperammonemia 0 trials
- Infantile hypertrophic cardiomyopathy due to MRPL44 deficiency 0 trials
- Lethal left ventricular non-compaction-seizures-hypotonia-cataract-developmental delay syndrome 0 trials
- Leukoencephalopathy-thalamus and brainstem anomalies-high lactate syndrome 0 trials
- Mitochondrial hypertrophic cardiomyopathy with lactic acidosis due to MTO1 deficiency 0 trials
- Mitochondrial proton-transporting ATP synthase complex deficiency 0 trials Sub-types →
- Severe X-linked mitochondrial encephalomyopathy 0 trials
-
4 sub-types
- Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 1 0 trials
- Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 2 0 trials
- Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 3 0 trials
- Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 4 0 trials
-
Hereditary spastic paraplegia 55 0 trials
-
Hereditary spastic paraplegia 77 0 trials
-
1 sub-type
-
Optic atrophy 3 0 trials
-
Spastic ataxia 3 0 trials
-
Spastic ataxia 4 0 trials
-
Spinocerebellar ataxia type 28 0 trials
Most studied deeper sub-types
-
Two drugs aim to restore energy factories in rare muscle disease
Disease control Recruiting nowResearchers are testing a combination of two drugs, doxecitine and doxribtimine, in adults with thymidine kinase 2 (TK2) deficiency, a rare genetic condition that causes muscle weakness and breathing problems. The study will enroll about 15 adults with moderate to severe disease.…
Phase 2 • Sponsor: Cristina Domínguez González • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Could stem cells restore sight in damaged eyes?
Disease control Recruiting nowThis study tests whether injecting a person's own bone marrow stem cells into or near the eye can help treat various retinal and optic nerve diseases, including age-related macular degeneration, retinitis pigmentosa, and glaucoma. Participants receive stem cell injections via dif…
Sponsor: MD Stem Cells • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New eye drug hopes to slow inherited blindness
Disease control Recruiting nowThis early-stage study tests a new medicine called PYC-001, given as an injection into the eye, for people with a rare genetic eye disease (autosomal dominant optic atrophy) caused by a change in the OPA1 gene. The main goal is to check the safety of different doses and schedules…
Phase 1/2 • Sponsor: PYC Therapeutics • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Experimental eye drug hopes to restore sight in rare blindness
Disease control Recruiting nowThis phase 3 trial tests an experimental drug called sepofarsen in 32 people with Leber congenital amaurosis (LCA), a rare genetic condition that causes severe vision loss from birth. The drug is injected into one eye, while the other eye gets a placebo, to see if it safely impro…
Phase 3 • Sponsor: Laboratoires Thea • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Rare disease drug now available through expanded access
Disease control Expanded accessThis program provides access to two experimental drugs, doxecitine and doxribtimine, for people with thymine kinase 2 deficiency (TK2d), a rare genetic disorder that can cause severe muscle weakness and early death. It is for children and adults who have a confirmed TK2 gene muta…
Sponsor: UCB BIOSCIENCES, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Could a common supplement ease gulf war illness symptoms?
Disease control Recruiting nowThis study tests whether a high-quality form of coenzyme Q10, a natural substance, can help reduce symptoms and improve daily life in veterans with Gulf War illness. Researchers will compare the supplement to a placebo in 192 veterans. The goal is to see if this approach offers a…
Phase 3 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Balance-Restoring implant shows promise for dizziness sufferers
Disease control Recruiting nowThis study follows 15 adults (ages 22–90) with severe, long-term balance disorders caused by inner ear damage. Participants have already received a vestibular implant, a device that electrically stimulates the balance nerve to help restore steadiness and clear vision during movem…
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Gene therapy aims to restore sight in rare inherited blindness
Disease control Recruiting nowThis study tests a gene therapy called GS010 for people with Leber hereditary optic neuropathy (LHON), a genetic condition that causes rapid vision loss. Researchers will give the treatment as an injection into the eye at two different doses to see if it improves vision and mitoc…
Phase 2 • Sponsor: GenSight Biologics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Can probiotics and coenzyme Q10 boost gum health during pregnancy?
Disease control Recruiting nowThis study tests whether adding a daily probiotic tablet and a coenzyme Q10 toothpaste to standard gum cleaning can improve oral health in pregnant women. Forty pregnant women will be split into two groups: one gets the probiotic plus Q10 toothpaste, the other gets only the Q10 t…
Sponsor: University of Pavia • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Inner ear implant aims to steady older adults with chronic dizziness
Disease control Recruiting nowThis study tests a vestibular implant in 15 older adults (ages 65-90) with chronic balance issues due to bilateral vestibular hypofunction. The implant electrically stimulates the inner ear to improve balance and vision. Researchers will measure changes in gait and eye reflexes o…
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Inner ear implant aims to restore balance in dizzy patients
Disease control Recruiting nowThis study tests a vestibular implant, a device surgically placed in the inner ear to electrically stimulate balance nerves. It aims to improve balance, posture, and vision in up to 8 adults with bilateral vestibular hypofunction, a condition causing chronic dizziness and instabi…
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Can home exercise and mindfulness help people with rare brain diseases walk and sleep better?
Symptom relief Recruiting nowResearchers are testing whether a home-based program combining adapted exercise and mindfulness training can improve walking ability and sleep quality in people with rare neurodegenerative diseases such as leukodystrophy, ataxia, and adrenomyeloneuropathy. The study enrolls about…
Sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc. • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Hope for mitochondrial disease: new drug targets debilitating fatigue
Symptom relief Recruiting nowThis study tests whether the drug sonlicromanol can reduce fatigue and improve physical abilities like balance and leg strength in adults with a specific genetic form of mitochondrial disease. About 220 participants will take either the drug or a placebo twice daily for 52 weeks.…
Phase 3 • Sponsor: Khondrion BV • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
New drug aims to ease fatigue in mitochondrial disease
Symptom relief Recruiting nowThis Phase 2 trial tests whether KL1333 can reduce fatigue and improve leg strength in adults with primary mitochondrial disease, a genetic condition that affects energy production. About 180 participants will receive either KL1333 or a placebo twice daily for 48 weeks. The study…
Phase 2 • Sponsor: Pharming Technologies B.V. • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
New rehab program aims to ease symptoms of rare neurological disorders
Symptom relief Recruiting nowThis study tests a 12-week supervised rehabilitation program for people with two rare genetic conditions that cause walking and balance problems (spastic ataxias). The program includes twice-weekly therapy sessions and once-weekly pool exercises. Researchers want to see if it red…
Sponsor: Laval University • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
NIH launches study to uncover link between infections and mitochondrial disease
Knowledge-focused Recruiting nowThis study at the National Institutes of Health looks at how infections can worsen symptoms in people with mitochondrial disease, a group of disorders that affect energy production in cells. Researchers will evaluate participants' immune systems through blood tests, physical exam…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
New laser device could revolutionize eye disease detection
Knowledge-focused Recruiting nowThis study is testing a new non-invasive device that uses laser speckle to measure blood flow and structure inside the eye. Researchers will compare these images with standard vision tests in 500 people with various retinal conditions. The goal is to see if this technology can be…
Sponsor: Randy Kardon • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Worldwide data pool could pave the way for mitochondrial disease trials
Knowledge-focused Recruiting nowThis study creates a global registry for people with mitochondrial disorders—rare diseases that affect energy production in cells. By collecting health data from 6,000 participants worldwide, researchers aim to understand how these diseases progress and identify the best ways to …
Sponsor: LMU Klinikum • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Thousands join fight against blindness by sharing their stories
Knowledge-focused Recruiting nowThis registry collects information from people with inherited retinal diseases, like retinitis pigmentosa and Stargardt disease. Participants share their symptoms, family history, and genetic test results online. The goal is to help researchers understand these rare diseases and …
Sponsor: Foundation Fighting Blindness • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Massive genetic diabetes hunt launches in china
Knowledge-focused Recruiting nowThis study is creating a large digital registry to find and understand rare forms of diabetes caused by a single gene (monogenic diabetes). Researchers will enroll up to 5,000 people in China who were diagnosed with diabetes at a young age and test their DNA. The goal is to learn…
Sponsor: Tianjin Medical University General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Scientists launch massive mitochondrial disease registry to unlock secrets of rare disorders
Knowledge-focused Recruiting nowThis study is creating a large registry and tissue bank for people with mitochondrial disorders. Researchers will collect medical information and samples from up to 1,000 participants, including those diagnosed with or suspected to have a mitochondrial disease. The goal is to gat…
Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
DNA hunt for rare brain disease genes begins
Knowledge-focused Recruiting nowThis study collects DNA from up to 1,000 adults with progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), multiple system atrophy (MSA), or related conditions, plus their family members. Researchers will sequence participants' whole genomes to find genetic variants …
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Can a simple blood test predict blindness before it starts?
Knowledge-focused Recruiting nowThis study looks at people who carry genetic changes linked to Leber Hereditary Optic Neuropathy (LHON) but still have normal vision. Researchers want to see if certain chemicals in the blood and tears can signal early nerve damage in the eye, before vision loss occurs. The goal …
Sponsor: Hôpital Necker-Enfants Malades • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
Massive leukodystrophy biobank aims to unlock disease secrets
Knowledge-focused Recruiting nowThis study collects medical information and biological samples (like blood or tissue) from up to 12,000 people with leukodystrophies—rare disorders that damage the brain's white matter. Researchers will use this data to find new genetic causes, develop biomarkers for future trial…
Sponsor: Children's Hospital of Philadelphia • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
Blood and skin samples could unlock new mitochondrial disease treatments
Knowledge-focused Recruiting nowThis study collects blood and skin samples from 100 people with primary mitochondrial diseases and healthy volunteers aged 3 to 85. Researchers will study how different mitochondrial mutations affect cell function and look for biomarkers. The samples will also help test a new the…
Sponsor: Minovia Therapeutics Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC